<code id='A399F3F488'></code><style id='A399F3F488'></style>
    • <acronym id='A399F3F488'></acronym>
      <center id='A399F3F488'><center id='A399F3F488'><tfoot id='A399F3F488'></tfoot></center><abbr id='A399F3F488'><dir id='A399F3F488'><tfoot id='A399F3F488'></tfoot><noframes id='A399F3F488'>

    • <optgroup id='A399F3F488'><strike id='A399F3F488'><sup id='A399F3F488'></sup></strike><code id='A399F3F488'></code></optgroup>
        1. <b id='A399F3F488'><label id='A399F3F488'><select id='A399F3F488'><dt id='A399F3F488'><span id='A399F3F488'></span></dt></select></label></b><u id='A399F3F488'></u>
          <i id='A399F3F488'><strike id='A399F3F488'><tt id='A399F3F488'><pre id='A399F3F488'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:Wikipedia    - browse:84345
          Adobe

          LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

          The deal includes up to another $400 million in payments if certain milestones are met.

          advertisement

          Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          entertainment